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Abstract
This review attempts to outline the alternative measures and interventions used in bloodless surgery in the field of
gynecologic oncology and demonstrate their effectiveness. Nowadays, as increasingly more patients are expressing
their fears concerning the potential risks accompanying allogenic transfusion of blood products, putting the theory
of bloodless surgery into practice seems to gaining greater acceptance. An increasing number of institutions
appear to be successfully adopting approaches that minimize blood usage for all patients treated for gynecologic
malignancies. Preoperative, intraoperative and postoperative measures are required, such as optimization of red
blood cell mass, adequate preoperative plan and invasive hemostatic procedures, assisting anesthetic techniques,
individualization of anemia tolerance, autologous blood donation, normovolemic hemodilution, intraoperative cell
salvage and pharmacologic agents for controlling blood loss. An individualised management plan of experienced
personnel adopting a multidisciplinary team approach should be available to establish non-blood management
strategies, and not only on demand of the patient, in the field of gynecologic oncology with the use of drugs,
devices and surgical-medical techniques.
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Review
With the advent of technology and advanced procedures
in the field of medicine, an emerging issue of restricting
allogenic blood transfusion has arisen. The medical
knowledge gained in the care of Jehovah Witnesses has
turned the concept of restriction of blood transfusions
into reality and redirected transfusion medicine towards
a more blood conservation oriented management [1].
Bloodless surgery schemes are part of a multidisciplinary
approach to patient care that involves all the measures
and clinical strategies that are taken in order to prevent
or at least minimise blood loss without allogenic trans-
fusion [2,3]. Current and emerging advances have
offered a new approach to the surgical management of
patients that refuse an allogenic blood transfusion.
Nowadays, increasingly more patients are expressing
their fears concerning the potential risks accompanying
the transfusion of blood products and requesting non-
blood surgical management; the potential hazardous
effects of allogenic transfusion can be categorised into
infectious and non-infectious risks as well as effects of
immunologic etiology [4]. Implications of blood transfu-
sion occur more often in patients treated for hematolo-
gic disorder or malignancy at a rate of 1% to 6% [5,6].
There is growing concern regarding viral contamina-
tion of blood with the human immunodeficiency virus,
hepatitis B and C viruses, Ebstein-Barr virus, human
T-cell lymphotropic viruses, cytomegalovirus, non A and
non B hepatitis viruses; quite rare infections result from
t h eW e s tN i l ev i r u sa n dp a r a s i t e ss u c ha sb a b e s i o s i s ,
Chagas disease and malaria [7,8].
Non-infectious complications of blood transfusion
mainly involve transfusion errors, occurring at a rate of
1 in 12, 000 transfusions performed, with fatality rates
of 1 death in 600, 000 transfusion errors [9,10], as well
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complications include adult respiratory distress syn-
drome, hypothermia, hemosiderosis, arrhythmia, hypo-
calcemia and hypomagnesemia [4]. Among the effects of
immunologic etiology, as a result of blood transfusion,
are reactions of acute and delayed hemolysis, fever,
allergic reactions, post-transfusion purpura and transfu-
sion-related acute lung injury [11].
Finally, some patients, such as Jehovah Witnesses, ada-
mantly refuse the transfusion of blood and its products
on the basis of their religious beliefs, even when they
are exposed to life threatening situations. Such rights of
self-determination are highly respected and have driven
large medical institutes to establish Bloodless Surgical
Measures and Schemes [12]. Today, many centers
worldwide and over 50 in the United States alone prac-
tise bloodless surgery [13].
Blood transfusion in the surgical management of gyne-
cologic oncology patients seems to be a common
approach [14]. A considerable percentage of women
undergoing abdominal hysterectomy (12.4%-16.7%) need
to be transfused with blood or its products [15,16].
Nevertheless, even in the field of gynecologic oncology,
surgeons are obliged to comply with the patients wish
for application of non-blood management strategies in
order to avoid blood-borne risks associated with blood
transfusion. Awareness and incorporation of such inter-
ventions is mandatory and should be followed by all sur-
geons and all patients have the right to benefit from the
application of these measures.
Gynecologic Oncology Surgery experience in blood
management
An independent review of the literature revealed seven-
teen clinical studies that have examined the effect of
blood conservation management schemes in patients
undergoing surgery for gynecologic malignancy or major
pelvic surgery in general [3,17-31] (Table 1).
As early as 1976, Mays et al presented the infusion of
iron dextran diluted in 1000 ml normal saline in 51
patients undergoing gynecologic surgery [17]. A great
hemoglobin response of 1.9 gr per decilitre per week
was demonstrated in this group of patients. No allergies
occurred and it proved to be a safe and reliable method.
Some published studies have investigated the impact of
avoiding allogenic blood tra n s f u s i o no nt h eo u t c o m eo f
patients undergoing major pelvic operations, treated for
gynecologic malignancies [18,21,23,26,30]. Bonakdar et
al [18] retrospectively reviewed 164 Jehovah Witnesses
undergoing major gynecologic and obstetrical interven-
tions without blood transfusion comparing them to 164
control patients. The study added effectual evidence to
the notion that major gynecologic interventions can be
performed without the need of blood and its products.
Eisenkop et al reported that perioperative blood transfu-
sion adversely affected the outcome of 68 patients
undergoing radical hysterectomy for cervical cancer
stage IB compared to 58 patients treated the same way,
but not transfused. The disease recurred in 14.7% of the
transfused group, while recurrence of the disease was
3.4% in the non-transfused group (p = 0.035) [21].
The recurrence of gynecologic malignancy was not
demonstrated after allogenic blood transfusion in the
study of Look et al, who examined 154 patients operated
for squamous vulvar cancer. He divided patients into
two groups: transfusion was given to 57 patients while
the remaining 96 received no blood. Both groups
revealed similar disease recurrence rates [23]. These
results are in line with those of Monk’s study, who tried
to evaluate the overall survival and time to recurrence
among 131 patients transfused during radical hysterect-
omy for cervical cancer stage IA2-IIA and 134 patients
who were offered the same operation for the same dis-
ease but were not perioperatively transfused. No differ-
ence was noted between the two groups [26]. Finally,
Massiah concluded in his own study that major, inter-
mediate and minor gynecological procedures can be
successfully performed in Jehovah Witnesses. Among
the 64 procedures, there were 14 major gynecological
operations [30].
An effective preoperative measure to decrease perio-
perative blood loss and therefore minimise the need for
blood transfusion is presented by Takemura et al [20].
Transcatheter arterial embolisation in three cases of cer-
vical adenocarcinoma stage III was carried out preopera-
tively, in order to stop hemorrhage. The method proved
to be quite effective. The same preoperative method of
arterial embolisation was used by Nagarsheth et al
before operating on a 52-year-old woman for a pelvic
mass of 40 cm [31]. Bilateral uterine artery embolisation
was attempted together with other measures to mini-
mise blood transfusion preoperatively, such as weekly
erythropoietin, iron and folate therapy. Intraoperative
measures included recombinant factor VIIa and salvage
of 280 ml of red blood cells. O’Dwyer described his
experience on autologous blood donation preoperatively
in 168 women undergoing abdominal hysterectomy; it
was presented by the authors as a safe and reasonable
transfusion practice [24].
Intraoperative measures for controlling blood loss and
minimising allogenic blood transfusion in the field of
gynecologic oncology have also been described. Powell
et al presented the effect of nitroglycerine based hypovo-
lemic general anesthesia during radical hysterectomy
and pelvic node dissection in 26 patients [19].
Compared to the control group, the guided hypotension
during surgery seemed to decrease blood loss by 70%
and shorten operating time by 29.5%. Consequently,
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of patients in the control group (82% vs 11.5%). Intrao-
perative hemodilution was attempted by Kelley and his
associates, who used an extracorporeal circulation device
(Haemonetics-V50 Cell Separator) in order to conserve
blood during surgery in 8 women treated with extensive
pelvic operations [25]. Two women accepted homolo-
gous transfusion, while the mean estimated blood loss
was calculated at 75 to 2000 ml. Connor et al, on the
other hand, divided 71 women undergoing radical hys-
terectomy for early cervical cancer into two groups.
Intraoperative autologous blood collection was per-
formed in both groups; 31 women received their own
blood collected by Cell Saver and 41 women were not
autotransfused. Connor concluded that intraoperative
autologous blood collection decreases the need for
homologous transfusion and does not facilitate co-trans-
fusion of malignant cells
27. Mirhashemi and his associ-
ates described the use of autologous blood transfusion
in 50 women undergoing radical hysterectomy type III
for early cervical cancer. There seemed to be no com-
promising malignancy outcome. Last but not least,
Nagarsheth described the surgical removal of a 12.7 kg
leiomyosarcoma without allogenic blood transfusion
[31]. During the operation, recombinant factor VIIa was
used together with cell salvage of 282 ml concentrated
blood reinfused after filtering with a leukocyte depletion
filter. Nagarsheth reported two more cases in which the
same technique of cell savage was used [31]. He rein-
fused 400 ml of salvaged blood into a 58-year-old
woman operated for ovarian adenocarcinoma and 170
ml of salvaged blood into a 49-year-old female operated
on for a large pelvic mass, which proved to be a gastro-
intestinal stromal tumor. In all three cases, the leukocyte
depletion filtering system was used. The woman suffer-
ing from the gastrointestinal tumor died of the disease
one year later.
Concentrated albumin infusion has been described
by Florica et al as a useful postoperative recovery tool
in women who undergo pelvic exenteration [22].
Postoperatively, one group of 10 women received an
albumin 25% infusion coupled with crystalloids, while
18 women received the crystalloid infusion only. The
overall outcome in the albumin infusion group proved
to be better in terms of stable postoperative course
and length of stay in the Intensive Care Unit for those
patients offered such major operations. Moreover,
measures such as Epoietin Alpha and pressure pack for
pelvic hemorrhage have been efficient in controlling
blood loss postoperatively and decreasing allogenic
transfusion requirements [28,29]. Epoietin Alpha has
been associated with hemoglobin increase in gynecolo-
gic cancer patients receiving chemotherapy as a weekly
dose [28].
Table 1 Clinical studies evaluating blood conservation methods in major pelvic surgery and gynecologic cancer
patients
Study author/year Number of
patients
operation/pathology Methods of blood conservation
Mays 1976 [17] 51 Gyn surgery/obstet. Iron-dextran
Bonakdar 1982 [18] 164 Major gyn surgery/obstet. No transfusion
Powell 1983 [19] 26 Radical hysterectomy &pelvic lymphadenectomy Nitroglycerine hypotensive anesthesia
Takemura 1989 [20] 3 Stage III cervical adenocarcinoma Preoperative transcatheter arterial embolisation
Eisencop 1990 [21] 58 Radical hysterectomy & retroperitoneal lymph node
dissection: stage IB cervical cancer
Non transfused vs transfused perioperatively
Florica 1991 [22] 28 Pelvic exenteration Albumin infusion & crystalloids postoperatively
Look 1993 [23] 97 Squamous vulvar carcinoma Non transfused vs transfused postoperatively
O’Dwyer 1993 [24] 168 Abdominal hysterectomy Autologous blood transfusion
Kelley 1994 [25] 8 Extensive pelvic operations Perioperative normovolemic hemodilution/homologous
transfusion
Monk 1995 [26] 134 Radical hysterectomy: stage IA2-IIA cervical cancer Non transfused vs transfused peri/postoperatively
Connor 1995 [27] 31 Radical hysterectomy for early cervical cancers Intraoperative autologous blood collection &
autotransfusion
Mirhashemi 1999 [42] 50 Radical hysterectomy type III for erly cervical cancer Intraoperative autologous blood transfusion
Stovall 2001 [28] Gynecologic cancer patients under chemotherapy Epoetin Alpha
Dildy 2006 [29] 1 hysterectomy Pelvic pressure pack
Massiah 2006 [30] 14 Major gynaecological procedures No transfusion(Jehovah’s witnesses)
Nagarsheth 2007 [3] 1 leiomyosarcoma Iron, folate, erythropoietin, uterine artery embolisation,
recombinant VIIa, cell salvage, crystalloids
Nagarsheth 2009 [31] 3 Leiomyosarcoma, ovarian adenocarcinoma,
pelvic mass
Blood salvage
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Gynecologic oncologists commonly deal with massive
hemorrhage during major pelvic operations and quite
often an emergency intervention is required to save the
patient’s life or deal with acute blood loss. So far, no
organised plan for bloodless surgery in gynecologic
oncology has been established, apart from the results
presented at the 2006 International Gynecologic Cancer
Society Meeting and the 2006 Society for the Advance-
ment of Blood Management Meeting [32]. In the inter-
est of simplicity, interventions used in bloodless surgery
can be categorised into preoperative, intraoperative and
postoperative measures.
Preoperative measures
Am o s ti m p o r t a n ta s p e c ti nt h es u r g i c a lm a n a g e m e n t
of those gynecologic oncology patients who are hesi-
tant to receive blood transfusions is that of appropriate
preoperative counselling. Surgeons should be knowl-
edgeable and skilled in advanced non-blood techni-
ques; they should inform the patient of available
alternatives to transfusion, discuss the risk-benefit ratio
of all these measures and propose the best strategies. A
specially prepared consent form that clearly outlines
the necessary therapeutic options in each case and the
strategies accepted by the patient should be offered
preoperatively. Each and every woman is considered
responsible for any decision concerning management
of her health and has the right to accept or refuse an
applied treatment option. Similarly, gynecologic oncol-
ogists should respect patients’ beliefs and informed
choices.
Previous studies have revealed anemia in a significant
percentage of patients assigned to elective surgery that
can vary from 5% to 75% [33,34]. The best option would
be to optimise hemoglobin level before surgery and
reinforce red blood cell mass formation with the admin-
istration of oral or intravenous iron, vitamin B12 or
folic acid preparations. Oral iron seems to be a good
choice, but quite often intravenous iron is recom-
mended at 1 to 2 weeks intervals [4]. A hemoglobin of
13 gr/dl can be considered an acceptable goal preopera-
tively [35].
Another and more effective alternative for the correc-
tion of preoperative anemia is the administration of
recombinant human erythropoietin (rHuEPO). Its action
is mainly based on its effect on bone marrow which in
turn increases red blood cell mass [36]. Nevertheless,
the use of erythropoietin stimulating agents (ESA) has
provoked concerns regarding safety when administered
to optimise haemoglobin levels exceeding 12 gr/dl, due
to thromboembolic and cardiovascular events reported
[37]. Moreover, still under investigation is the use of
erythropoietins in cancer patients, as such agents might
act as growth factors for certain tumors [38]. FDA has
therefore proposed the use of erythropoietins in anemia
related to chemotherapy in oncologic patients [37].
Preoperative autologous blood donation is another
alternative. This actually involves the donation of 4
units of whole blood preoperatively over a 4-week per-
iod; the blood is then stored and given to the patient, as
required, with autologous transfusion [39]. Nevertheless,
a limitation to autologous donation is a hemoglobin of
no less than 11 gr/dl and its infectious potential [4].
Autologous blood donation may decrease the incidence
of immunosuppression reported in homologous blood
transfusions, in gynecologic oncology [4].
Finally, in the hands of well-trained interventional
radiologists, uterine artery embolisation has been
reported in the literature as an effective preoperative
technique that minimises intraoperative blood loss
[3,20]. Potential risks include fertility compromise, the
classic post-embolisation syndrome (infection, peritoneal
and intrauterine adhesions) and irradiation hazard [40].
Intraoperative measures
Intraoperative blood loss could be effectively minimised
by meticulous hemostasis, reduction of operative time,
hypotensive anesthetic techniques, intraoperative hemo-
dilution, blood salvage and pharmacological hemostatic
agents.
Hypotensive states during major pelvic surgery, using
general anesthetic agents coupled with nitroglycerine,
effectively minimise blood loss with mean arterial pres-
sure reaching as low as 60 mmHg [19]. Contraindica-
tions to this method are cerebrovascular disease, severe
renal and hepatic compromise, myocardial ischemia,
hypovolemic status and peripheral vascular disorder
[19].
Hemodiluting methods, either hypervolemic or isovo-
lemic, are rarely utilised in the field of gynecology [4].
Hypervolemic hemodilution demands that large
volumes of solutions - crystalloids or colloids - are
infused in volume boluses calculated at 3 times the
calculated blood loss, so as to maintain a greater
amount of haemoglobin [11,14]. Greater intravascular
oncotic pressure with smaller volumes can be accom-
plished more effectively with colloids rather than crys-
talloids [11]. During hypovolemic hemodilution, 1 to 2
units of whole blood are preoperatively collected and
substituted with volumes of solutions. The blood can
then be easily transfused back to the patient against
hypovolemia [41]. Severe anemia, pregnancy and use of
beta-blockers represent contraindications for hemodi-
luting methods [4].
Perioperative autotransfusion or blood salvage, is a
technique during which blood is collected intraopera-
tively from the patient’s abdomen or pelvis, processed
through leukocyte depletion filters or irradiation mea-
sures [42,43] and then transfused back to the patient
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method is currently restricted in cancer patients due to
the potential hematogenous dissemination of malignant
cells [31]; indications would be abdominal uterine myo-
mectomy, ectopic pregnancy operations and abdominal
hysterectomy for benign disease [44,45]. Nevertheless,
studies in the literature have shown that the use of
blood salvage on gynaecological oncology patients poses
no such risk [27,31,42]. Potential risks accompanying
the method are fat and air embolism and infection [4].
Aminocaproic acid, desmopressin acetate, aprotinin,
tranexamic acid, phytonadione and vasopressin are
hemostatic drugs also utilised for the control of intrao-
perative hemorrhage [44]. Aprotinin exerts antifibrinoly-
tic and anti-inflammatory action; though usually
preferred over the other agents, it often causes throm-
boembolic sequelae and renal compromise, and is quite
costly [46]. Additionally, recombinant factor VIIa
(rFVIIa) has contributed to a great reduction in blood
usage, even in the field of gynecologic oncology,
although its use in managing perioperative coagulopathy
is ‘off-labelled’
3. Intraoperatively, the use of rFVIIa may
provoke thromboembolic events at a rate of 44%
[46,47]. Hence, pharmacologic hemostatic agents should
be applied with caution and not to all cases of intrao-
perative bleeding.
Postoperative measures
Postoperative measures include meticulous postoperative
monitoring of the patient, early recognition of blood loss
[39,47], minimisation of phlebotomy blood sampling
[39], enhancement of hemopoiesis [45], optimisation of
cardiopulmonary status [48] and minimisation of oxygen
consumption to provide adequate perfusion to tissues
[14]. Albumin may be continuously infused by gynecolo-
gic oncologists early on postoperatively in order to sta-
bilise blood pressure and establish fluid load [22].
Epoietin Alpha (Epo) can be used in anemic cancer
patients under chemotherapy [49]; similarly, Granulo-
cyte-macrophage colony-stimulating factors and platelet
growth factor could be considered in the treatment of
chemotherapy-induced thrombocytopenia in women suf-
fering from gynecologic malignancies [4].
Conclusion
In the field of gynecologic oncology, the perioperative
management of patients who refuse allogenic blood
transfusion, poses limitations for surgeons and renders
mandatory the establishment of Bloodless Surgery Pro-
grams; each gynecologist should be informed about the
available blood conservation methods and order their
application if needed, optimising the patients’ outcome
without allogenic blood transfusion. Such actions must
be initiated by a multidisciplinary approach with the
coordination of all members of the bloodless medicine
and surgery team such as surgeons, anaesthesiologists,
intensivists, pharmacists, nursing stuff and hematolo-
gists. The efficient cooperation of all members of the
team will guide institutions towards a marked blood
usage reduction over time.
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